PharmiWeb.com - Global Pharma News & Resources
05-Dec-2018

Protagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

Protagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

PR Newswire

NEWARK, Calif., Dec. 5, 2018

NEWARK, Calif., Dec. 5, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York.

Presentation details:

Event:

BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference


Date:

Wednesday, Dec. 12, 2018


Time:

9:20 a.m. EST


A live and archived audio webcast of the presentation can be accessed by visiting the Investors page of the Protagonist Therapeutics website at http://investors.protagonist-inc.com.

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-200 is an oral peptide interleukin-23 receptor antagonist in development for the treatment of Crohn's disease, and it has completed Phase 1 studies in healthy volunteers. The company has entered into a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200. PN-10943 is an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide that is under development for treatment of ulcerative colitis. Protagonist is also developing an injectable hepcidin mimetic, PTG-300, for the potential treatment of anemia and iron overload related to rare blood diseases with an initial focus on beta thalassemia. A global Phase 2 trial in patients with beta thalassemia will be initiated by the end of 2018.

Protagonist is headquartered in Newark, California, with pre-clinical and clinical staff in California and discovery operations in both California and Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-bmo-capital-markets-2018-prescriptions-for-success-healthcare-conference-300760052.html

SOURCE Protagonist Therapeutics, Inc.

Editor Details

Last Updated: 05-Dec-2018